Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
AssigneeMapreg
InventorsGeorge F. KOOB, Barbara JEAN MASON, Olivier GEORGE, Etienne BAULIEU, Isabelle VILLEY
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.
Claims20
A method for treating or preventing relapse of a substance use disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of formula (I):
- wherein:
- each of independently represents a single or a double bond;
- R1 represents a C1-C4 alkyl;
- R2 represents —CO—;
- —CH(OH)— or —CH(O—COCH3)—;
- and
- R3 represents H or CHCl2 and R4 represents H or CH3, or R3 and R4 together represent
- or a pharmaceutically acceptable salt thereof.
A method for treating or preventing relapse of an alcohol use disorder (AUD) in a subject in need thereof, comprising administering to said patient a therapeutically efficient amount of compound 3β-methoxy-pregna-5-ene-20-one of formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.